# Veeva Systems (VEEV) Q2 FY2027 earnings

Results filed 2026-08-26 for the quarter ended 2026-07-31. Source page: https://earnings.opennash.com/companies/veev/2027-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1393052/000139305226000032/0001393052-26-000032-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Veeva's Vault CRM had its best quarter ever, with 12 top 20 biopharma commitments, while Veeva Falcon agentic AI for clinical, regulatory and safety moves toward first go-lives.

Veeva's push into AI-driven applications gained traction. Vault CRM has more than 180 customers live, including five top 20 biopharmas, and a top 20 biopharma rolled out Vault CRM with the Agentic Call Report to its full U.S. field team. Development Cloud and Quality Cloud saw broad adoption: a large biopharma selected Veeva EDC, Veeva Safety passed 100 customers, and Quality added more than 30 new customers. Veeva also acquired Copli and launched Veeva Falcon MLR.
Management is steering toward agentic labor: Veeva Falcon has five early adopters and is on track for initial go-lives this year, alongside new standard agents in Vault AI. The main tension is execution. Falcon is a new product that must be readied and proven with early adopters, while Veeva's services business is growing faster than subscriptions as customers adopt new products. Headcount is up 11% year over year.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenues | $928.0 million | up 18% year over year | GAAP |
| Net income | $273.4 million | up 37% year over year | GAAP |
| Diluted EPS | $1.66 | up from $1.19 one year ago | GAAP |
| Non-GAAP diluted EPS | $2.35 | up from $1.99 one year ago | non-GAAP |
| Operating income | $275.0 million | up 40% year over year | GAAP |
| Non-GAAP operating income | $415.9 million | up 18% year over year | non-GAAP |
| Gross margin | 75.0% | from 75.3% a year ago | GAAP |
| Operating margin | 29.6% | from 24.8% a year ago | GAAP |
| Operating cash flow | $238,709 | from $238,433 a year ago | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Subscription revenues | $766.8 million | up 16% year over year |
| Commercial Solutions subscription | $347,389 | from $307,523 a year ago |
| R&D and Quality Solutions subscription | $419,375 | from $351,660 a year ago |
| Professional services and other | $161,199 | from $129,898 a year ago |
| Vault CRM customers live | more than 180 |  |
| Veeva Safety customers | 100 total customers |  |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Total revenues | fiscal third quarter ending October 31, 2026 | $932 and $935 million |
| Non-GAAP operating income | fiscal third quarter ending October 31, 2026 | $417 and $420 million |
| Non-GAAP diluted EPS | fiscal third quarter ending October 31, 2026 | $2.33 and $2.34 |
| Total revenues | fiscal year ending January 31, 2027 | $3,682 and $3,687 million |
| Non-GAAP operating income | fiscal year ending January 31, 2027 | ~$1,640 million |
| Non-GAAP diluted EPS | fiscal year ending January 31, 2027 | ~$9.21 |
| Non-GAAP operating cash flow | fiscal year ending January 31, 2027 | ~$1,600 million |

## Key takeaways

1. **Vault CRM momentum builds among largest biopharmas** More than 180 customers are live, including five top 20 biopharmas, and two top 20 plus one large enterprise biopharma committed in August, bringing top 20 commitments to 12. This strengthens Veeva's position in its core commercial market.
2. **Agentic CRM is reaching full field deployment** A top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter. It is a concrete example of AI moving into production use.
3. **Veeva Falcon targets clinical, regulatory and safety labor** Falcon is described as an agentic labor platform with five early adopters and initial go-lives expected this year. Veeva also launched Veeva Falcon MLR to automate content reviews.
4. **Vault AI broadens with standard and custom agents** August brought new standard agents, broader capabilities for existing agents, and advanced tools for building custom agents. This extends AI from Veeva's own agents to customer-built ones.
5. **R&D and Quality footprint keeps widening** A large enterprise biopharma selected Veeva EDC on top of eTMF, CTMS and Study Startup, and Veeva Safety won its second top 20 biopharma for Safety Workbench. Quality added more than 30 new customers, with 20 or more wins each across QualityDocs, QMS and Training.

## Questions

**What were the main product developments at Veeva this quarter?** Veeva launched Veeva Falcon MLR, advanced Vault AI with new standard agents and custom agent tools, and acquired Copli. Veeva Falcon, its agentic platform for clinical, regulatory and safety, has five early adopters.
**How is Vault CRM doing with large pharma customers?** More than 180 customers are live, including five top 20 biopharmas. Top 20 commitments reached 12 globally after two top 20 biopharmas and one large enterprise biopharma committed in August.
**When will Veeva Falcon go live?** Veeva says Falcon is on track for initial go-lives this year, with five early adopters working with it now.
**Is Veeva gaining ground in clinical, safety and quality software?** Yes, according to the release. A large biopharma selected Veeva EDC, Veeva Safety passed 100 customers with a second top 20 Safety Workbench win, and Quality added more than 30 new customers.
**How is Veeva positioning itself around AI?** Veeva describes AI as the next big chapter and combines applications, agents, data and consulting for life sciences. Its AI offerings include Vault AI agents, the Agentic Call Report and Falcon agentic labor.

## Slides and investor documents

- [Investor Presentation](https://s206.q4cdn.com/200001835/files/doc_financials/2027/q2/VEEV-Q2-27-Earnings-Presentation.pdf) (Slide deck)
- [Prepared Remarks](https://s206.q4cdn.com/200001835/files/doc_financials/2027/q2/Veeva-Q2-27-Earnings-Prepared-Remarks.pdf) (CFO commentary)
- [Webcast](https://events.q4inc.com/attendee/883220744) (Webcast replay)
- [Financial Results](https://s206.q4cdn.com/200001835/files/doc_financials/2027/q2/VEEV-Q2-27-Earnings-Release.pdf) (Document)
- [Financial Results (HTML)](https://ir.veeva.com/news/news-details/2026/Veeva-Announces-Fiscal-2027-Second-Quarter-Results/default.aspx) (Document)

